{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:42:43Z","timestamp":1783010563816,"version":"3.54.6"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2015,7,24]],"date-time":"2015-07-24T00:00:00Z","timestamp":1437696000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Qual Life Res"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s11136-015-1039-y","type":"journal-article","created":{"date-parts":[[2015,7,23]],"date-time":"2015-07-23T04:11:53Z","timestamp":1437624713000},"page":"2895-2906","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study"],"prefix":"10.1007","volume":"24","author":[{"given":"K. M.","family":"Holtzer-Goor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. R.","family":"Schaafsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Joosten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. F. M.","family":"Posthuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Wittebol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. C.","family":"Huijgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. J. M.","family":"Mattijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Vreugdenhil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. G.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Erjavec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. W.","family":"Wijermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. M. G. J.","family":"Daenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. G.","family":"van der Hem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. H. J.","family":"van Oers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. A.","family":"Uyl-de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,7,24]]},"reference":[{"key":"1039_CR1","unstructured":"Altekruse, S. F., Kosary, C. L., Krapcho, M., Neyman, N., Aminou, R., Waldron, W., et al. (Eds.). SEER cancer statistics review, 1975\u20132007. Bethesda, MD: National Cancer Institute. http:\/\/seer.cancer.gov\/csr\/1975_2007\/ . Accessed July 2010."},{"key":"1039_CR2","unstructured":"Cancer Research UK. (2008). Data table: Incidence cases and rates for males, females and persons in the UK, England, Wales, Scotland and Northern Ireland. http:\/\/publications.cancerresearchuk.org\/cancerstats\/statsincidence\/dtinccountries.html 2011: 2. Accessed Aug 2013."},{"key":"1039_CR3","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.ejca.2011.06.053","volume":"48","author":"EC Broek van den","year":"2011","unstructured":"van den Broek, E. C., Kater, A. P., van de Schans, S. A., Karim-Kos, H. E., Janssen-Heijnen, M. L., Peters, W. G., et al. (2011). Chronic lymphocytic leukaemia in the Netherlands: Trends in incidence, treatment and survival, 1989\u20132008. European Journal of Cancer, 48, 889\u2013895.","journal-title":"European Journal of Cancer"},{"key":"1039_CR4","doi-asserted-by":"crossref","first-page":"435","DOI":"10.7326\/0003-4819-145-6-200609190-00007","volume":"145","author":"T Shanafelt","year":"2006","unstructured":"Shanafelt, T., Byrd, J., Call, T., Zent, C. S., & Kay, N. (2006). Initial management of newly diagnosed, early stage, chronic lymphocytic leukemia: An update for the internist. Annals of Internal Medicine, 145, 435\u2013447.","journal-title":"Annals of Internal Medicine"},{"key":"1039_CR5","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-129-7-199810010-00010","volume":"129","author":"EJ Anaissie","year":"1998","unstructured":"Anaissie, E. J., Kontoyiannis, D. P., O\u00e2\u20ac\u2122Brien, S., Kantarjian, H., Robertson, L., Lerner, S., & Keating, M. J. (1998). Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Annals of Internal Medicine, 129, 559\u2013566.","journal-title":"Annals of Internal Medicine"},{"key":"1039_CR6","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1200\/JCO.2001.19.16.3611","volume":"19","author":"VA Morrison","year":"2001","unstructured":"Morrison, V. A., Rai, K. R., Peterson, B. L., Kolitz, J. E., Elias, L., & Appelbaum, F. R. (2001). Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. Journal of Clinical Oncology, 19, 3611\u20133621.","journal-title":"Journal of Clinical Oncology"},{"key":"1039_CR7","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1080\/10428190500244183","volume":"46","author":"S Molica","year":"2005","unstructured":"Molica, S. (2005). Quality of life in chronic lymphocytic leukemia: A neglected issue. Leukemia and Lymphoma, 46, 1709\u20131714.","journal-title":"Leukemia and Lymphoma"},{"key":"1039_CR8","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/01.mjt.0000104489.93653.0f","volume":"12","author":"JM Stephens","year":"2005","unstructured":"Stephens, J. M., Gramegna, P., Laskin, B., Botteman, M. F., & Pashos, C. L. (2005). Chronic lymphocytic leukemia: Economic burden and quality of life: Literature review. American Journal of Therapeutics, 12, 460\u2013466.","journal-title":"American Journal of Therapeutics"},{"key":"1039_CR9","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.ejca.2008.03.017","volume":"44","author":"F Efficace","year":"2008","unstructured":"Efficace, F., Kemmler, G., Vignetti, M., Mandelli, F., Molica, S., & Holzner, B. (2008). Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials\u00e2\u20ac\u201dA systematic review to evaluate the added value in supporting clinical decision making. European Journal of Cancer, 44, 1497\u20131506.","journal-title":"European Journal of Cancer"},{"key":"1039_CR10","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/j.1365-2141.2008.07407.x","volume":"143","author":"M Else","year":"2008","unstructured":"Else, M., Smith, A. G., Cocks, K., Richards, S. M., Crofts, S., Wade, R., et al. (2008). Patients\u00e2\u20ac\u2122 experience of chronic lymphocytic leukaemia: Baseline health-related quality of life results from the LRF CLL4 trial. British Journal of Haematology, 143, 690\u2013697.","journal-title":"British Journal of Haematology"},{"key":"1039_CR11","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1200\/JCO.2006.05.6929","volume":"25","author":"BF Eichhorst","year":"2007","unstructured":"Eichhorst, B. F., Busch, R., Obwandner, T., Kuhn-Hallek, I., Herschbach, P., Hallek, M., & German CLL Study Group. (2007). Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: A study by the German CLL Study Group. Journal of Clinical Oncology, 25, 1722\u20131731.","journal-title":"Journal of Clinical Oncology"},{"key":"1039_CR12","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","volume":"370","author":"D Catovsky","year":"2007","unstructured":"Catovsky, D., Richards, S., Matutes, E., Oscier, D., Dyer, M. J., Bezares, R. F., et al. (2007). Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial. The Lancet, 370, 230\u2013239.","journal-title":"The Lancet"},{"issue":"July","key":"1039_CR13","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.3109\/10428194.2011.649479","volume":"53","author":"M Else","year":"2012","unstructured":"Else, M., Cocks, K., Crofts, S., Wade, R., Richards, S. M., Catovsky, D., et al. (2012). Quality of life in chronic lymphocytic leukemia: 5-Year results from the multicenter randomized LRF CLL4 trial. Leukemia and Lymphoma, 53(July), 1289\u20131298.","journal-title":"Leukemia and Lymphoma"},{"key":"1039_CR14","doi-asserted-by":"crossref","unstructured":"Kay, N. E. (2012). Predicting clinical outcome in B-chronic lymphocytic leukemia. In ASCO educational book (pp. 394\u2013398). http:\/\/meetinglibrary.asco.org\/content\/145-114","DOI":"10.14694\/EdBook_AM.2012.32.145"},{"key":"1039_CR15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2141.2007.06791.x","volume":"139","author":"TD Shanafelt","year":"2007","unstructured":"Shanafelt, T. D., Bowen, D., Venkat, C., Slager, S. L., Zent, C. S., & Kay, N. E. (2007). Quality of life in chronic lymphocytic leukemia: An international survey of 1482 patients. British Journal of Haematology, 139, 255\u2013264.","journal-title":"British Journal of Haematology"},{"key":"1039_CR16","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1600-0609.2004.00233.x","volume":"72","author":"B Holzner","year":"2004","unstructured":"Holzner, B., Kemmler, G., Kopp, M., Nguyen-Van-Tam, D., Sperner-Unterweger, B., & Greil, R. (2004). Quality of life of patients with chronic lymphocytic leukemia: Results of a longitudinal investigation over 1 yr. European Journal of Hematology, 72, 381\u2013389.","journal-title":"European Journal of Hematology"},{"key":"1039_CR17","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1007\/s00520-013-1854-z","volume":"21","author":"CL Pashos","year":"2013","unstructured":"Pashos, C. L., Flowers, C. R., Kay, N. E., Weiss, M., Lamanna, N., Farber, C., et al. (2013). Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia. Supportive Care in Cancer, 21, 2853\u20132860.","journal-title":"Supportive Care in Cancer"},{"key":"1039_CR18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.leukres.2013.10.029","volume":"38","author":"KM Holtzer-Goor","year":"2014","unstructured":"Holtzer-Goor, K. M., Bouwmans-Frijters, C. A., Schaafsma, M. R., de Weerdt, O., Joosten, P., Posthuma, E. F. M., et al. (2014). Real-world costs of chronic lymphocytic leukaemia in the Netherlands. Leukemia Research, 38, 84\u201390.","journal-title":"Leukemia Research"},{"key":"1039_CR19","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85, 365\u2013376.","journal-title":"Journal of the National Cancer Institute"},{"key":"1039_CR20","volume-title":"The measurement and valuation of health status using EQ-5D: A European perspective; evidence from the EuroQol BIOMED Research Programme","year":"2003","unstructured":"Brooks, R., Rabin, R., & De Charro, F. (Eds.). (2003). The measurement and valuation of health status using EQ-5D: A European perspective; evidence from the EuroQol BIOMED Research Programme (1st ed.). Dordrecht: Kluwer Academic Publishers.","edition":"1"},{"key":"1039_CR21","unstructured":"Kind, P., & Macran, S. (2002). Levelling the playing field: Increasing the number of response categories in EQ-5D. In Kind and Macran. York: University of York."},{"key":"1039_CR22","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1023\/A:1008890401133","volume":"7","author":"MA Sprangers","year":"1998","unstructured":"Sprangers, M. A., Cull, A., Groenvold, M., Bjordal, K., Blazeby, J., & Aaronson, N. K. (1998). The European Organization for Research and Treatment of Cancer approach to developing questionnaire modules: An update and overview. EORTC Quality of Life Study Group. Quality of Life Research, 7, 291\u2013300.","journal-title":"Quality of Life Research"},{"key":"1039_CR23","volume-title":"The EORTC QLQ-C30 scoring manual","author":"PM Fayers","year":"2001","unstructured":"Fayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., Bottomley, A., & on behalf of the EORTC Quality of Life Group. (2001). The EORTC QLQ-C30 scoring manual (3rd ed.). Brussels: European Organisation for Research and Treatment of Cancer.","edition":"3"},{"key":"1039_CR24","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","volume":"16","author":"D Osoba","year":"1998","unstructured":"Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998). Interpreting the significance of changes in health-related quality-of-life scores. Journal of Clinical Oncology, 16, 139\u2013144.","journal-title":"Journal of Clinical Oncology"},{"key":"1039_CR25","unstructured":"EORTC. Chronic lymphocytic leukaemia (QLQ-CLL16). http:\/\/groups.eortc.be\/qol\/chronic-lymphocytic-leukaemia-qlq-cll16 . Accessed Dec 2013."},{"key":"1039_CR26","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., et al. (2011). Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research, 20, 1727\u20131736.","journal-title":"Quality of Life Research"},{"key":"1039_CR27","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/hec.1124","volume":"15","author":"LM Lamers","year":"2006","unstructured":"Lamers, L. M., McDonnell, J., Stalmeier, P. F., Krabbe, P. F., & Busschbach, J. J. (2006). The Dutch tariff: Results and arguments for an effective design for national EQ-5D valuation studies. Health Economics, 15, 1121\u20131132.","journal-title":"Health Economics"},{"key":"1039_CR28","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/j.1524-4733.2009.00509.x","volume":"12","author":"S Bernert","year":"2009","unstructured":"Bernert, S., Fern\u00c3\u00a1ndez, A., Haro, J. M., K\u00c3\u00b6nig, H. H., Alonso, J., Vilagut, G., et al. (2009). Comparison of different valuation methods for population health status measured by the EQ-5D in three European countries. Value in Health, 12, 750\u2013758.","journal-title":"Value in Health"},{"key":"1039_CR29","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.ejca.2010.11.004","volume":"47","author":"LV Poll-Franse Van de","year":"2011","unstructured":"Van de Poll-Franse, L. V., Mols, F., Gundy, C. M., Creutzberg, C. L., Nout, R. A., Verdonck-de Leeuw, I. M., et al. (2011). Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general Dutch population. European Journal of Cancer, 47, 667\u2013675.","journal-title":"European Journal of Cancer"},{"key":"1039_CR30","volume-title":"A cost of illness and quality of life study in patients with B-cell chronic lymphocytic leukemia (CLL) in the Netherlands","author":"KM Holtzer-Goor","year":"2011","unstructured":"Holtzer-Goor, K. M., Bouwmans-Frijters, C. A., Schaafsma, M. R., & Uyl-de Groot, C. A. (2011). A cost of illness and quality of life study in patients with B-cell chronic lymphocytic leukemia (CLL) in the Netherlands. Rotterdam: Erasmus University Rotterdam."},{"issue":"Suppl 1","key":"1039_CR31","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.12-S1-4","volume":"12","author":"M Hofman","year":"2007","unstructured":"Hofman, M., Ryan, J. L., Figueroa-Moseley, C. D., Jean-Pierre, P., & Morrow, G. R. (2007). Cancer-related fatigue: The scale of the problem. The Oncologist, 12(Suppl 1), 4\u201310.","journal-title":"The Oncologist"},{"key":"1039_CR32","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","volume":"376","author":"M Hallek","year":"2010","unstructured":"Hallek, M., Fischer, K., Fingerle-Rowson, G., et al. (2010). Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. The Lancet, 376, 1164\u20131174.","journal-title":"The Lancet"},{"key":"1039_CR33","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1177\/0272989X11427761","volume":"32","author":"MM Versteegh","year":"2012","unstructured":"Versteegh, M. M., Leunis, A., Luime, J. J., Boggild, M., Uyl-de Groot, C. A., & Stolk, E. A. (2012). Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D. Medical Decision Making, 32, 554\u2013568.","journal-title":"Medical Decision Making"},{"key":"1039_CR34","unstructured":"Comprehensive Cancer Centre the Netherlands (IKNL). (2010). www.cijfersoverkanker.nl . Accessed Dec 2013."},{"key":"1039_CR35","first-page":"104","volume":"147","author":"AP Kater","year":"2003","unstructured":"Kater, A. P., & van Oers, M. H. (2003). Chronic lymphocytic leukemia: High time for a risk-adapted approach. Nederlands Tijdschrift voor Geneeskunde, 147, 104\u2013109.","journal-title":"Nederlands Tijdschrift voor Geneeskunde"}],"container-title":["Quality of Life Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-015-1039-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11136-015-1039-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-015-1039-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T17:52:24Z","timestamp":1599328344000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11136-015-1039-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,24]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["1039"],"URL":"https:\/\/doi.org\/10.1007\/s11136-015-1039-y","relation":{},"ISSN":["0962-9343","1573-2649"],"issn-type":[{"value":"0962-9343","type":"print"},{"value":"1573-2649","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,24]]}}}